V2 Receptor Antagonist; Tolvaptan
Hyponatremia is the most common electrolyte disorder in hospitalized patients. Many studies documented that it was related to increased morbidity and mortality in patients with congestive heart failure, liver cirrhosis, and neurologic diseases. Although knowledge of hyponatremia has been cumulated,...
Main Authors: | Yi, Joo-Hark, Shin, Hyun-Jong, Kim, Ho-Jung |
---|---|
Format: | Online |
Language: | English |
Published: |
The Korean Society of Electrolyte Metabolism
2011
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302906/ |
Similar Items
-
Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan
by: Gaglio, Paul, et al.
Published: (2012) -
Tolvaptan
by: Rangarajan, Bharath, et al.
Published: (2014) -
Tolvaptan, hyponatremia, and heart failure
by: Zmily, Hammam D, et al.
Published: (2011) -
Tolvaptan for the Treatment of Refractory Ascites
by: Kurosaki, Masayuki, et al.
Published: (2016) -
Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis
by: Iwamoto, Takuya, et al.
Published: (2016)